Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Change in Receivables (2021 - 2024)

IDEAYA Biosciences (IDYA) has disclosed Change in Receivables for 4 consecutive years, with -$2000.0 as the latest value for Q4 2024.

  • Quarterly Change in Receivables rose 99.97% to -$2000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$6.7 million through Sep 2024, down 305.38% year-over-year, with the annual reading at -$193000.0 for FY2023, 78.36% up from the prior year.
  • Change in Receivables hit -$2000.0 in Q4 2024 for IDEAYA Biosciences, down from $19000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $6.5 million in Q3 2023 to a low of -$6.7 million in Q4 2023.
  • Historically, Change in Receivables has averaged -$116187.5 across 4 years, with a median of -$8500.0 in 2024.
  • Biggest YoY gain for Change in Receivables was 1129.64% in 2022; the steepest drop was 3909.41% in 2022.
  • Year by year, Change in Receivables stood at $85000.0 in 2021, then crashed by 3909.41% to -$3.2 million in 2022, then plummeted by 106.45% to -$6.7 million in 2023, then soared by 99.97% to -$2000.0 in 2024.
  • Business Quant data shows Change in Receivables for IDYA at -$2000.0 in Q4 2024, $19000.0 in Q3 2024, and -$14000.0 in Q2 2024.